Research Article

P2Y₂ Receptor Induces *L. amazonensis* Infection Control in a Mechanism Dependent on Caspase-1 Activation and IL-1 β Secretion

Maria Luiza Thorstenberg,¹ Monique Daiane Andrade Martins,¹ Vanessa Figliuolo,¹ Claudia Lucia Martins Silva,² Luiz Eduardo Baggio Savio,¹ and Robson Coutinho-Silva¹

¹Laboratório de Imunofisiologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

²Laboratório de Farmacologia Bioquímica e Molecular, Instituto de Ciências Biomédicas, Universidade Federal do Rio de Janeiro, Brazil

Correspondence should be addressed to Robson Coutinho-Silva; rcsilva@biof.ufrj.br

Received 26 June 2020; Accepted 7 September 2020; Published 1 October 2020

Academic Editor: Tae Jin lee

Copyright © 2020 Maria Luiza Thorstenberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Leishmaniasis is a neglected tropical disease caused by an intracellular parasite of the genus *Leishmania*. Damage-associated molecular patterns (DAMPs) such as UTP and ATP are released from infected cells and, once in the extracellular medium, activate P2 purinergic receptors. P2Y₂ and P2X7 receptors cooperate to control *Leishmania amazonensis* infection. NLRP3 inflammasome activation and IL-1 β release resulting from P2X7 activation are important for outcomes of *L. amazonensis* infection. The cytokine IL-1 β is required for the control of intracellular parasites. In the present study, we investigated the involvement of the P2Y₂ receptor in the activation of NLRP3 inflammasome elements (caspase-1 and 11) and IL-1 β secretion during *L. amazonensis* infection in peritoneal macrophages as well as in a murine model of cutaneous leishmaniasis. We found that 2-thio-UTP (a selective P2Y₂ agonist) reduced parasite load in *L. amazonensis*-infected murine macrophages and in the footpads and lymph nodes of infected mice. The antiparasitic effects triggered by P2Y₂ activation were not observed when cells were pretreated with a caspase-1 inhibitor (Z-YVAD-FMK) or in macrophages from caspase-1/11 knockout mice (CASP-1,11^{-/-}). We also found that UTP treatment induced IL-1 β secretion in wild-type (WT) infected macrophages but not in cells from CASP-1,11^{-/-} mice, suggesting that caspase-1 activation by UTP triggers IL-1 β secretion in *L. amazonensis*-infected macrophages. Infected cells pretreated with IL-1R antagonist did not show reduced parasitic load after UTP and ATP treatment. Our *in vivo* experiments also showed that intralesional UTP treatment reduced both parasite load (in the footpads and popliteal lymph nodes) and lesion size in wild-type (WT) and CASP-11^{-/-} but not in CASP-1,11^{-/-} mice. Taken together, our findings suggest that P2Y₂R activation induces CASP-1 activation and IL-1 β secretion during *L. amazonensis* infection. IL-1 β /IL-1R signaling is crucial for P2Y₂R-mediated protective immune response in an experimental model of cutaneous leishmaniasis.

1. Introduction

Leishmaniasis is a vector-borne disease caused by flagellated protozoans of the genus *Leishmania*. This disease represents a spectrum of neglected tropical diseases that are endemic in 98 countries worldwide [1]. The clinical manifestations range from cutaneous or mucocutaneous lesions to lethal visceral pathology. Cutaneous leishmaniasis, whose symp-

toms range from local ulcers to mucosal tissue destruction, can be caused by *L. amazonensis*, *L. major*, *L. braziliensis*, and *L. guayanaensis* [2].

In humans, *Leishmania* promastigotes are injected into the dermis (i.e., through the bite of an infected sandfly) and establish infection in phagocytic cells [3]. The recognition of pathogen-associated molecular patterns (PAMPs) by phagocytes leads to the release of damage-associated

molecular patterns (DAMPs) such as the extracellular nucleotides ATP (eATP) and UTP (eUTP) that are involved in the killing of intracellular pathogens through the activation of P2 receptors ([4, 5]. P2 purinergic/pyrimidinergic receptors can be subdivided into metabotropic G-protein-coupled P2Y (P2Y_{1,2,4,6,11-14}) and ionotropic P2X receptors (P2X₁₋₇) [6]. The following agonists activate P2 receptors: P2X and P2Y₁₁-ATP; P2Y_{2,4}-ATP and -UTP; P2Y₁, P2Y₁₂, and P2Y₁₃-ADP; P2Y₆-UDP; and P2Y₁₄-UDP-glucose [7]. P2Y receptors (P2YR) can be constitutively expressed or regulated under pathological conditions [8]. Metabotropic G-coupled-proteins such as calcium-sensing receptor and P2YR were reported to be implicated in NLRP3 inflammasome activation in inflammatory models [9–13].

Evidence supports the involvement of the noncanonical NLRP3 inflammasome assembly in the elimination of *L. amazonensis* infection by P2X7R triggering, acting as an important platform to improve host leishmanicidal mechanisms. Nevertheless, the mechanisms involved in the activation of this inflammasome in leishmaniasis remain elusive [14, 15]. ATP/P2X7R signaling during *L. amazonensis* infection has been partially elucidated during the last decade; it is assumed to be the most potent canonical activator of the NLRP3 inflammasome [16] and more recently in non-canonical activation of NLRP3 inflammasome assembly [14, 17, 18]. We previously demonstrated that the antiparasite immune response attributed to the P2YR agonist UTP involves paracrine activation of the P2X7 receptor (P2X7R) and PANX-1 channels in macrophages from mice infected with *L. amazonensis* [19]; UTP induces production and release of reactive oxygen species (ROS), nitrite oxide (NO) [20, 21], and leukotriene B₄ (LTB₄) [19] that is assumed to be crucial for parasite death. In addition to these inflammatory mediators, IL-1 β mediates the control of intracellular parasite infections [4] [22]. In the present study, we investigated caspase-1/IL-1 β axis activation in the protective immune response induced by P2Y₂ receptor activation in an experimental model of cutaneous leishmaniasis.

2. Materials and Methods

2.1. Chemicals. UTP (uridine triphosphate), ATP (adenosine triphosphate), Dulbecco's modified Eagle's medium (DMEM), and 199 medium were purchased from Sigma-Aldrich (St. Louis, MO, USA); 2-thio-UTP and FMK-Z-YVAD were from Tocris (Bristol, UK).

2.2. Mice. The experiments, maintenance, and care of mice were carried out according to the guidelines of the Brazilian College of Animal Experimentation (COBEA). We used wild-type BALB/c and C57BL/6 (Jackson Laboratory, USA), as well as CASP-1,11 and CASP-11 knockout mice (CASP-1,11^{-/-} and CASP-11^{-/-} against the C57BL/6 background) (Genentech Laboratory, South San Francisco, CA, USA). CASP-1,11^{-/-} and CASP-11^{-/-} mice were maintained at the Laboratory of Transgenic Animals of the Federal University of Rio de Janeiro (UFRJ, RJ, Brazil). The mice were housed in a temperature-controlled room (22°C) with a light/dark cycle (12 h). Food and water were provided *ad libitum*. The

animal experimentation protocols used in this study were approved by the Ethics Committee on the Use of Animals (CEUA) from the IBCCF, UFRJ, document no. 077/15.

2.3. Parasite Culture. We used *L. amazonensis* (MHOM/BR/Josefa) strain in both *in vitro* and *in vivo* experiments. Amastigotes isolated from mouse lesions (from BALB/c mice) were allowed to transform into axenic promastigote forms by growth at 24°C, for 7 days, in 199 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS; Gibco BRL, 2% male human urine, 1% L-glutamine and 0.25% hemin). Promastigotes in the late stationary phase of growth until the tenth passage were used to preserve parasite virulence.

2.4. Cell Culture and Infection. Resident macrophages were harvested from the peritoneal cavity by washes with cold phosphate buffer saline (PBS). Cells were directly seeded on culture plates (in DMEM-supplemented medium, at 37°C, with 5% CO₂) for 1 h and washed gently with PBS (twice) to remove nonadherent cells. The cells were cultured for 24 h in DMEM supplemented (10% FBS and 100 units penicillin/streptomycin) at 37°C (and 5% CO₂) and infected for 4 h or 1 h with *L. amazonensis* promastigotes (MOI ratio 10:1, Leishmania: macrophage) at 37°C. The noninternalized parasites were removed by extensive washing with sterile PBS. Then, infected cells were maintained in an incubator at 37°C and 5% CO₂ until the moment of stimulation.

2.5. In Vitro Stimulus and Inhibitor Treatments. Infected macrophages (48 h after infection) were treated with 10 μ M Z-YVAD-FMK, 2 μ M Z-LEVD-FMK, or IL-1Ra (100 ng/mL) for 30 minutes before stimulation with UTP (100 μ M) or ATP (50, 100, or 500 μ M) for an additional 30 minutes at 37°C and 5% CO₂. Then, cell monolayers were washed with PBS and maintained in DMEM supplemented (10% FBS and 100 units penicillin/streptomycin) at 37°C (and 5% CO₂) for 24 h, when infection index and cytokine production were measured.

2.6. Macrophage Infection Index. Intracellular parasite loads were analyzed as previously described [19]. Briefly, cells were infected and treated with nucleotides and were fixed onto slides, stained using a panoptic stain (Laborclin®, PR, Brazil), and counted using a Primo Star light microscope (Zeiss, Germany), with a 40x objective (100x for representative pictures). Images were acquired using a Bx51 camera (Olympus, Tokyo Japan) operated using the Cell[^]F software. We calculated the “infection index,” representing the overall infection load, based on the count of about 100 cells in a total of five fields to obtain the number of infected macrophages and the average number of parasites per macrophage. Individual amastigotes were clearly visible in the cytoplasm of infected macrophages. The results were expressed as the infection index II = (%infected macrophages) $\times$ (amastigotes/infected macrophage)/100.

2.7. Murine Model of Infection and In Vivo Treatments. Female BALB/c mice, wild-type (WT), CASP-1,11^{-/-}, and CASP-11^{-/-} C57BL/6 (8–12 weeks old) were infected in the

dermis of the footpad by intradermal injection of 10^6 *L. amazonensis* promastigotes in PBS. Intralesional treatment with 20 μ L of 10 μ M 2-thio-UTP, 1 mM UTP (pH = 7.4), or vehicle (for 3 weeks, twice a week) started 7 days postinfection (d.p.i.). Lesion growth was calculated by evaluation of the “swelling” (thickness of the infected footpad – thickness of the uninfected footpad from the same mouse), using a traditional caliper (Mitutoyo®). Forty-eight hours after the final injection (26 d.p.i.), the animals were euthanized, and the infected footpad and popliteal lymph nodes were removed and dissociated (in M199-supplemented culture medium) for parasitic load determination.

2.8. Parasite Number in Mouse Tissues. The parasite load of *L. amazonensis* in infected tissues was determined using a limiting dilution assay, as previously described [19, 23]. Mice were euthanized in a CO₂ chamber, followed by cervical dislocation. The footpads and lymph nodes were collected and weighed, and cells from the whole footpad and draining lymph nodes were dissociated using a cell strainer 40 μ m (BD®) in PBS. Large pieces of tissue debris were removed by centrifugation at 150 g; cells were separated by centrifugation at 2,000 g for 10 min and resuspended in supplemented M199. Samples were cultured in 96-well flat-bottom microtiter plates (BD®, USA) at 26–28°C. After a minimum of 7 days, wells were examined using phase-contrast microscopy in an inverted microscope (NIKON TMS, JP) and scored as “positive” or “negative” for the presence of parasites. Wells were scored “positive” when at least one parasite was observed per well.

2.9. Cytokine Levels. Measuring IL-1 β released in cell supernatants, peritoneal macrophages from WT, and CASP-1,11^{-/-} mice were plated in 96-well plates (2.0×10^5) and infected with promastigotes of *L. amazonensis* (MOI 10:1) as described in Section 2.4. Then, cells were treated with 100 μ M UTP or 3 mM ATP for 30 min. Cells were washed after 30 min and maintained at 37°C for an additional 4 h, and the supernatants were collected for further analyses. Enzyme-linked immunosorbent assays (ELISA) were performed using commercial kits, as instructed by the manufacturer (R&D Systems, Minneapolis, MN, USA). We also measured cytokine production in footpads from WT, CASP-1,11^{-/-}, and CASP-11^{-/-} mice. Briefly, the infected footpads were collected and processed as described above. IL-1 β and IL-1 α levels were measured using ELISA with commercial kits, as instructed by the manufacturer (R&D Systems, Minneapolis, MN, USA). Protein concentrations were determined using the bicinchoninic acid method (Thermo Fisher, BCA protein assay kit, Rockford, IL, USA), and cytokine levels in tissue were corrected for by the total amount of protein.

2.10. Statistical Analysis. Statistical analyses were performed using the Student's *t*-test to compare two groups. For more than two groups, data were analyzed using the one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison post hoc test, using the Prism 5.0 software (GraphPad Software, La Jolla, CA, USA). Differences

between experimental groups were considered statistically significant when $P < 0.05$.

3. Results

3.1. P2Y₂R Contributes to *L. amazonensis* Infection Control. We recently reported that UTP-intralesional treatment elicited a Th₁ immune response in an experimental model of cutaneous leishmaniasis [21], suggesting the involvement of P2Y₂R. Here, we evaluated whether the intralesional treatment with a selective P2Y₂R agonist (2-thio-UTP) would promote *L. amazonensis* control in BALB/c mice. As shown in Figure 1(a), tissues were harvested for analysis at 26 d.p.i. We found that 2-thio-UTP treatment reduced the parasitic load in the footpads (Figure 1(b)) and draining lymph nodes (Figure 1(c)), as well as the number of leukocytes in the draining lymph nodes of infected mice (Figure 1(d)) when compared to those of control mice. We also investigated the antiparasitic effect attributed to 2-thio-UTP (range 0.025–1 μ M) and UTP (range 1–100 μ M) in infected macrophages. We found that all concentrations of UTP significantly reduced the infection index in both BALB/c (Figure 1(f)) and C57BL/6 WT macrophages (Figure 1(h)). Antiparasitic effects of 2-thio-UTP treatment were observed at concentrations ranging from 0.05 to 1 μ M in both BALB/c (Figure 1(g)) and C57BL/6 WT macrophages (Figure 1(i)). These results suggest that P2Y₂R activation contributes to the control of *L. amazonensis* infection.

3.2. Caspase-1 Is Required to P2Y₂R-Mediated *L. amazonensis* Control in Macrophages. Previously, we showed that antiparasite effects attributed by UTP and ATP involve P2X₇R and PANX-1 channels in infected macrophages [19]. We also reported that antiparasitic immune responses triggered by the ATP/P2X₇R/PANX-1 axis require NLRP3 inflammasome activation in macrophages infected with *L. amazonensis* [14]. Here, we determined whether CASP-1 activation (an essential component of the NLRP3 inflammasome) participates in infection control mediated by eUTP. We found that the antileishmanial effects of UTP were absent in infected macrophages from mice genetically deficient for CASP-1,11 enzymes (CASP-1,11^{-/-} mice) (Figures 2(b)–2(f)). When we blocked CASP-1 with Z-YVAD-FMK (CASP-1 inhibitor), the antiparasitic effects attributed to UTP treatment were abrogated (Figures 3(b)–3(f)). By contrast, the antiparasitic effects of UTP were significant in macrophages from CASP-11^{-/-} mice and in WT macrophages treated with Z-LEVD-FMK (CASP-11 inhibitor) (Supplementary Figure 1). These findings suggest that the activity of CASP-1 but not CASP-11 is relevant to *L. amazonensis* control mediated by the P2Y₂ receptor.

3.3. P2Y₂R Stimulation Promotes IL-1 β Secretion from *L. amazonensis*-Infected Macrophages. IL-1 β is an important proinflammatory cytokine produced in response to several pathogens, and its secretion is induced by inflammasome activation in a P2X₇-dependent manner during *L. amazonensis* infection [24]. Therefore, we determined whether activation of the inflammasome via UTP/P2Y₂R would result in

FIGURE 1: P2Y₂R selective agonist 2-thio-UTP improves host resistance against *L. amazonensis*. (a) Schematics showing the animal model of *in vivo* experiments. BALB/c mice ($n = 6/\text{group}$) were subcutaneously injected in the footpad with 10^6 promastigotes (*L. amazonensis* at stationary phase). From 7 days postinfection (d.p.i.), mice were treated with $10 \mu\text{M}$ 2-thio-UTP in $20 \mu\text{L}$ PBS and injected into the infected footpad twice a week for 3 weeks (six doses). (b–d) Animals were euthanized 26 d.p.i., and the footpads and popliteal lymph nodes were removed and used for further analysis. (b) Parasitic loads in the footpads and lymph nodes (c) were determined using a limiting dilution assay (LDA). (d) Leukocyte numbers from popliteal lymph nodes. (e) Schematics showing the design of *in vitro* experiments. BALB/c (f, g) and C57Bl/6 (WT) (h, i) macrophages infected for 48 h were treated for 30 min with UTP (1–100 μM UTP) (f–h) or 2-thio-UTP (0.025–1 μM) (g–i). After 30 h, cells were fixed, stained with the panoptotic kit, and observed with light microscopy. The effect of treatments on infection was quantified by determining the “infection index” (% of infection $\times$ number of amastigotes/total number of cells)/100; normalized to the untreated), by direct counting under the light microscope. Data represent mean $\pm$ SEM of three independent experiments performed in triplicate, with pools of cells from four animals each experiment. * $P < 0.05$ relative to the untreated group (one-way analysis of variance followed by Tukey’s test).

FIGURE 2: Control of *L. amazonensis* infection by UTP requires CASP-1,11. (a) Schematics showing the infection and treatments. Representative images of infected peritoneal macrophages from WT (b, c) and CASP-1,11^{-/-} (d, e) treated with UTP (100 μ M) (d, e) for 30 min or left untreated (b, c). The antiparasitic effect of UTP treatment was evaluated through the “infection index” (f). Data represent mean $\pm$ SEM of three independent experiments performed in triplicate, with pools of 3–4 animals in each experiment. *** $P < 0.0001$ relative to the untreated group (one-way analysis of variance followed by Tukey’s test).

the secretion of IL-1 β by *L. amazonensis*-infected cells. We found that UTP treatment induced IL-1 β secretion in WT-infected macrophages but not in macrophages from CASP-1/11^{-/-} mice (Figure 4(a)), suggesting that activation of the canonical NLRP3 inflammasome by eUTP triggers IL-1 β secretion in *L. amazonensis*-infected macrophages in a caspase-1-dependent fashion. Treatment with UTP or ATP did not reduce the parasitic load in infected macrophages pretreated with IL-1R antagonist (Figures 4(b)–4(i)), suggesting that IL-1R signaling is essential to *L. amazonensis* control mediated by P2X and P2Y receptors.

3.4. Treatment with UTP Promotes the Control of In Vivo *L. amazonensis* Infection through Caspase-1 Activation and IL-

1 β Production. To confirm the importance of the CASP-1 activation by UTP/P2Y₂ activation, we evaluated the requirement of CASP-1 in the protection elicited by UTP treatment during *L. amazonensis* infection *in vivo*. We injected UTP at intervals of 3–4 days, from 7 days postinfection in the footpads of WT, CASP-1,11^{-/-}, and CASP-11^{-/-} mice infected with 10⁶ promastigotes of *L. amazonensis*. Mice were euthanized 26 days postinfection, and lesion development (swelling) was measured during the development of leishmaniasis (Figure 5(a)). As depicted in Figure 5(b), WT mice treated with UTP showed significantly smaller lesion sizes and lower parasite loads (the final one both in the footpads and lymph nodes) than in control mice (Figures 5(b), 5(e), and 5(f)).

FIGURE 3: The antiparasitic effect by P2Y₂R requires CASP-1 activity. (a) Schematics showing the infection and treatments. Infected peritoneal macrophages from BALB/c were treated with UTP (100 μM) (c, e) for 30 min or left untreated (b) following Z-YVAD-FMK (2 μM) (d, e). The antiparasitic effect of UTP treatment was evaluated through the “infection index” (f). Data represent mean ± SEM of three independent experiments performed in triplicate, with pools of 3–4 animals in each experiment. ****P* < 0.0001 relative to the untreated group (one-way analysis of variance followed by Tukey’s test).

However, these protective effects were absent in CASP-1,11^{-/-} mice, where UTP treatment did not reduce either lesion size or parasite load (Figures 5(c), 5(e), and 5(f)). UTP treatment in CASP-11^{-/-} infected mice did not significantly decrease lesion size but rather induced a significant reduction in parasite load (Figures 5(d), 5(e), and 5(f)). Of note, both knockouts showed increased parasite loads when compared to infected WT mice (Figures 5(e) and 5(f)), as previously reported [15].

We also evaluated whether CASP-1 and CASP-11 were relevant to the production of IL-1β and IL-1α in mice treated with UTP. The footpads from infected WT and CASP-11^{-/-} mice treated with UTP showed higher levels of IL-1β, as compared to the control footpads (Figure 5(g)). However, no increase in IL-1β was found in the footpads of UTP-treated CASP-1,11^{-/-} mice (Figure 5(g)), suggesting that CASP-1 is involved in UTP-induced IL-1β production. Levels of IL-1α did not differ in the footpads from WT,

CASP-1,11^{-/-}, and CASP-11^{-/-} mice after UTP treatment (Figure 5(h)).

4. Discussion

Cutaneous leishmaniasis affects millions of people worldwide. Nevertheless, the host defense mechanisms that are modulated to control parasite replication and treat the disease are not thoroughly characterized, and several aspects of the disease remain poorly understood [25]. We previously reported the involvement of purinergic receptors, including P2Y₂R and P2X7R, in the control of *L. amazonensis* infection *in vitro* and *in vivo* [4, 19]. These receptors induce the activation of several microbicidal mechanisms in host cells during infection (i.e., NO, ROS, LTB₄ production) [20, 21, 26, 27]. Here, we identified a protective mechanism triggered by P2Y₂R, using incubation with either a specific agonist for P2Y₂R, 2-thio UTP, or low concentrations of UTP (100 μM) or ATP

FIGURE 4: Control of *L. amazonensis* infection by UTP and ATP involves IL-1R signaling. (a) Peritoneal macrophages from WT and CASP1,11^{-/-} mice were infected with *L. amazonensis* promastigotes for 1 h and treated with UTP for 30 min. Cell culture supernatants were harvested 4 h later. Uninfected cells were primed with LPS (1 μ g/mL) for 2 h followed by ATP (3 mM), as the second signal (a positive control). IL-1 β was measured 6 h later in the positive control group. (b–d) BALB/c-infected macrophages untreated (e–g) or treated with IL-1Ra (100 ng/mL) for 30 min prior (c, f) UTP and (d, g) ATP pulse for 30 min. Twenty-four hours after nucleotide treatment, cells were fixed and stained using the panopti kit to measure parasitic load using the “infection index” (h, i). Data are mean $\pm$ SEM of three independent experiments performed in triplicate, with pools of 3–4 animals in each experiment. *** P < 0.0001 and ** P < 0.005 relative to the untreated group (one-way analysis of variance followed by Tukey’s test).

FIGURE 5: CASP-1 activity is necessary for the protective effects of UTP during *in vivo* infection with *L. amazonensis*. (a) Schematics showing the experimental approach of *in vivo* experiments. WT, CASP-1,11^{-/-}, and CASP-1,11^{-/-} mice ($n = 5$ and 6 /group) were infected with 10^6 *L. amazonensis*; following 7 d.p.i., we started the intralesional treatment with 1 mM UTP into the infected footpad twice a week for 3 weeks (six doses). (b–d) Swelling (thickness) was measured using a traditional Mitutoyo® caliper, and the lesion size was determined by the thickness of the infected footpad – thickness of the uninfected footpad from the same mouse. (e–h) Animals were euthanized 26 d.p.i. when the footpad and popliteal lymph nodes were excised and used to quantify parasite load and cytokine production. (e) Parasite loads in the footpads (f) and in popliteal lymph nodes from WT and CASP-1,11^{-/-} mice by limiting dilution assay (LDA). (g) IL-1β and (h) IL-1α production into the footpad was measured by ELISA. Data represent mean ± SEM values, $n = 5–6$ mice per group. ** $P < 0.01$ and * $P < 0.05$ in comparison to the untreated group (one-way analysis of variance followed by Tukey's test).

(50 μM) during *in vitro* infection with *L. amazonensis*. Parasite elimination upon P2Y₂R activation *in vitro* and *in vivo* depends on caspase-1 activation and IL-1R signaling.

The role of P2X₇R in the IL-1β maturation via NLRP3 inflammasome assembly in both infectious and inflamma-

tory disorders is currently accepted [16, 28, 29]. Jin et al. [10] also proposed a P2Y₂R-mediated inflammasome activation pathway [10]. Interestingly, inflammasome assembly and signaling are closely associated with the physiopathology of leishmaniasis [30–32]. We and others have shown that the

NLRP3 inflammasome is protective and contributes to restricting *L. amazonensis* parasite replication in macrophages as well as *in vivo* [30, 33, 34]. The canonical NLRP3 inflammasome promotes IL-1 β and IL-18 activation through the engagement of NLRP3, ASC, and caspase-1 activation. In addition to these components, the noncanonical NLRP3 inflammasome requires a caspase-11 expression for proper caspase-1 activation [35].

Despite the apparent importance of the inflammasome for disease outcomes, the mechanisms by which NLRP3 inflammasome is activated during *Leishmania* infection remain poorly understood. ROS production via dectin-1 and P2X7R activation appears to be involved in NLRP3 inflammasome activation [14, 34]. The mechanisms of NLRP3 inflammasome activation required for IL-1 β generation during infection by *Leishmania* have been recently elucidated. IL-1 β from a noncanonical NLRP3 source was implicated in the elimination of pathogens [36, 37] including *L. amazonensis* [14]. In support of this finding, caspase-11 was shown to be activated in response to the cytosolic delivery of *Leishmania* LPG in macrophages [30]. Previous *in vitro* studies from our group reported that ATP/P2X7 axis was critical for *L. amazonensis* control in a mechanism dependent on IL-1R signaling by noncanonical NLRP3 inflammasome activation [14, 24]. In these settings, *L. amazonensis* elimination by P2X7R activation was followed by LTB₄ release and subsequent activation of the NLRP3 complex and IL-1 β release, requiring the activation of both CASP-1 and CASP-11 [4, 14]. NLRP3 activation by LTB₄ depended on ROS induction [38]. Likewise, P2X7R activation triggered ROS production and the host immune response in several intracellular pathogen diseases, including *Toxoplasma gondii*, *Chlamydia* spp., and *Plasmodium chabaudi* infections [39–41].

P2X7R was also necessary for antiparasitic responses attributed to UTP/P2Y₂R in *L. amazonensis* infection [19]. The elimination of *L. amazonensis* *in vitro* triggered by P2Y₂R involves P2X7-dependent LTB₄ secretion, in a mechanism requiring pannexin-1. P2X7R expression was also required for *in vivo* control of *L. amazonensis* by UTP, supporting the notion of a collaborative effect among P2 receptors to improve the antiparasitic immune response in leishmaniasis [19]. In the present study, we showed, through *in vitro* and *in vivo* studies, that CASP-1 and IL-1R signaling, but not CASP-11, were necessary to boost host immune responses induced by P2Y₂R, contributing to protection against *L. amazonensis*.

Antileishmanial effects triggered by P2Y₂R involve two steps. The first one is mediated by ATP release with an autocrine/paracrine effect on P2X7R [19]. The second reveals a pathway of IL-1 β induction triggered by P2Y₂R (activated by low ATP concentrations). Corroborating our results, P2Y₂R signaling triggered inflammasome activation in several inflammatory models [9, 13], and caspase-1-mediated secretion of IL-1 β after activation of NLRP3 [9] and NLCR4 inflammasomes [42] after P2Y₂R activation have been reported.

In the present study, we showed that P2Y₂R induced lower levels of extracellular IL-1 β when compared to P2X7R engagement by exogenous ATP, even though the

technique used to measure extracellular nucleotides did not directly reflect their concentration around cells. These findings suggest that the P2X7R-dependent pathway triggered by P2Y₂R could be activated to a lesser extent than that of P2X7R activation triggered by exogenous ATP. P2X7 receptor activation and its effect on immune cells vary according to ATP levels. P2X7 receptor stimulation with low ATP (100 μ M) leads to the formation of a cation-selective channel. Its activation by high levels of ATP triggers the formation of a nonselective pore [43, 44]. The latter scenario is usually related to pronounced ROS production, inflammasome activation, and IL-1 β release in various systems [45]. High ATP levels can activate the P2X7R that acts as the second signal for noncanonical NLRP3 inflammasome activation during *L. amazonensis* infection. Chaves et al. [14] demonstrated activation of the noncanonical NLRP3 and IL-1 β release after P2X7R activation *in vitro* after incubation of infected macrophages with exogenous ATP (500 μ M) [14]. In this context, P2X7R activation by high exogenous ATP concentrations during infection with *L. amazonensis* might lead to higher levels of extracellular LTB₄, which in turn would favor ROS production and triggering of the noncanonical NLRP3 inflammasome assembly. Our data suggest that P2Y₂ receptor activation is not able to induce P2X7 receptor activation at a level that triggers activation of the noncanonical NLRP3 inflammasome assembly. Nevertheless, the exact inflammasome-related pathways triggered under these conditions are unknown and require further studies.

Our *in vivo* results showed that, while lack of CASP-1/11 abrogated IL-1 β induction and reduction in parasite load after activation of P2Y₂R, mice deficient in CASP-11 preserved an antileishmanial response after treatment with UTP. These findings suggest that, during *in vivo* infection by *L. amazonensis*, caspase-1 is the main source of IL-1 β and is responsible for controlling the parasitic infection. This pathway is further enhanced by P2Y₂R signaling. Even though P2X7R activation appears to enhance IL-1 β production through the noncanonical NLRP3 *in vitro* [14], its participation in the control of *in vivo* infection by *L. amazonensis* has not been addressed. It needs to be studied in depth before reaching further conclusions. Taken together, these data suggest that not only P2X7R but also P2Y₂R, a G-protein-coupled receptor, is involved in the activation of IL-1 β production/release in immune cells during infection with *L. amazonensis*. IL-1R activation, in turn, controls *L. amazonensis* infection. These results suggest that DAMPs boost the immune response against *L. amazonensis* infection via P2 receptors.

5. Conclusion

P2Y₂R activation by UTP/ATP induced CASP-1 activation and IL-1 β secretion in the context of *L. amazonensis* infection. IL-1 β /IL-1R signaling was crucial to P2Y₂R-mediated protective immune responses in an experimental model of cutaneous leishmaniasis. These findings suggest that P2Y₂R may be a possible therapeutic target to treat *L. amazonensis* infection by potentiating IL-1 β /IL-1R signaling and controlling parasite replication.

Data Availability

The file data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no competing or financial interests.

Acknowledgments

The authors wish to thank Pryscilla Braga, Fabiane Cristina Rodrigues, and Barbara Gabrielle Araujo for technical assistance. This work was supported by grants from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ, Brazil—E-26/010.002985/2014, E-26/203.027/2 015, E-26/202.774/2018, and E-26/202.701/2019).

Supplementary Materials

Supplementary Figure 1: infected peritoneal macrophages from BALB/c (A) were pretreated with Z-YVAD-FMK (2 μ M) for 30 minutes and then with 100 μ M UTP for another 30 minutes. Peritoneal macrophages from WT or CASP-11^{-/-} were infected and after 48 h treated or not with UTP (100 μ M) for 30 minutes (B). Twenty-four hours later, cells were fixed and stained with panoptic stain, and glass coverslips on slides were evaluated using the “infection index” by a direct count under light microscopy. Data represent mean $\pm$ SEM of three independent experiments performed in triplicate, with pools of 3–4 animals in each experiment. *** $P < 0.0001$ relative to the untreated group (one-way analysis of variance followed by Tukey’s test). (Supplementary Materials)

References

- [1] S. Burza, S. L. Croft, and M. Boelaert, “Leishmaniasis,” *The Lancet*, vol. 392, no. 10151, pp. 951–970, 2018.
- [2] J. Alvar, I. D. Vélez, C. Bern et al., “Leishmaniasis worldwide and global estimates of its incidence,” *PLoS One*, vol. 7, no. 5, article e35671, 2012.
- [3] D. Sacks and N. Noben-Trauth, “The immunology of susceptibility and resistance to *Leishmania major* in mice,” *Nature Reviews. Immunology*, vol. 2, no. 11, pp. 845–858, 2002.
- [4] M. M. Chaves, C. Marques-da-Silva, A. P. Monteiro, C. Canetti, and R. Coutinho-Silva, “Leukotriene B₄ modulates P2X₇ receptor-mediated *Leishmania amazonensis* elimination in murine macrophages,” *Journal of Immunology*, vol. 192, no. 10, pp. 4765–4773, 2014.
- [5] L. E. B. Savio and R. Coutinho-Silva, “Immunomodulatory effects of P2X₇ receptor in intracellular parasite infections,” *Current Opinion in Pharmacology*, vol. 47, pp. 53–58, 2019.
- [6] V. Ralevic and G. Burnstock, “Receptors for purines and pyrimidines,” *Pharmacological Reviews*, vol. 50, pp. 413–492, 1998.
- [7] K. A. Jacobson, E. G. Delicado, C. Gachet et al., “Update of P2Y receptor pharmacology: IUPHAR Review 27,” *British Journal of Pharmacology*, vol. 177, no. 11, pp. 2413–2433, 2020.
- [8] D. Le Duc, A. Schulz, V. Lede et al., “P2Y receptors in immune response and inflammation,” in *Advances in Immunology*, pp. 85–121, Elsevier, 2017.
- [9] L. Baron, A. Gombault, M. Fanny et al., “The NLRP3 inflammasome is activated by nanoparticles through ATP, ADP and adenosine,” *Cell Death & Disease*, vol. 6, p. 1629, 2015.
- [10] H. Jin, Y. S. Ko, and H. J. Kim, “P2Y₂R-mediated inflammasome activation is involved in tumor progression in breast cancer cells and in radiotherapy-resistant breast cancer,” *International Journal of Oncology*, vol. 53, pp. 1953–1966, 2018.
- [11] G. S. Lee, N. Subramanian, A. I. Kim et al., “The calcium-sensing receptor regulates the NLRP3 inflammasome through Ca²⁺ and cAMP,” *Nature*, vol. 492, no. 7427, pp. 123–127, 2012.
- [12] M. Rossol, M. Pierer, N. Raulien et al., “Extracellular Ca²⁺ is a danger signal activating the NLRP3 inflammasome through G protein-coupled calcium sensing receptors,” *Nature Communications*, vol. 3, no. 1, p. 1329, 2012.
- [13] T. Suzuki, K. Kohyama, K. Moriyama et al., “Extracellular ADP augments microglial inflammasome and NF-kappa B activation via the P2Y₁₂ receptor,” *European Journal of Immunology*, vol. 50, no. 2, pp. 205–219, 2019.
- [14] M. M. Chaves, D. A. Sinflorio, M. L. Thorstenberg et al., “Non-canonical NLRP3 inflammasome activation and IL-1 β signaling are necessary to *L. amazonensis* control mediated by P2X₇ receptor and leukotriene B₄,” *PLoS Pathogens*, vol. 15, article e1007887, 2019.
- [15] D. S. Lima-Junior, D. L. Costa, V. Carregaro et al., “Inflammasome-derived IL-1 β production induces nitric oxide-mediated resistance to *Leishmania*,” *Nature Medicine*, vol. 19, no. 7, pp. 909–915, 2013.
- [16] P. Pelegrin and A. Surprenant, “Pannexin-1 mediates large pore formation and interleukin-1 β release by the ATP-gated P2X₇ receptor,” *The EMBO Journal*, vol. 25, no. 21, pp. 5071–5082, 2006.
- [17] S. Rühl and P. Broz, “Caspase-11 activates a canonical NLRP3 inflammasome by promoting K⁽⁺⁾ efflux,” *European Journal of Immunology*, vol. 45, no. 10, pp. 2927–2936, 2015.
- [18] D. Yang, Y. He, R. Munoz-Planillo, Q. Liu, and G. Nunez, “Caspase-11 requires the pannexin-1 channel and the purinergic P2X₇ pore to mediate pyroptosis and endotoxin shock,” *Immunity*, vol. 43, no. 5, pp. 923–932, 2015.
- [19] M. L. Thorstenberg, M. V. Rangel Ferreira, N. Amorim et al., “Purinergic cooperation between P2Y₂ and P2X₇ receptors promote cutaneous leishmaniasis control: involvement of pannexin-1 and leukotrienes,” *Frontiers in Immunology*, vol. 9, p. 1531, 2018.
- [20] C. Marques-da-Silva, M. M. Chaves, S. P. Chaves et al., “Infection with *Leishmania amazonensis* upregulates purinergic receptor expression and induces host-cell susceptibility to UTP-mediated apoptosis,” *Cellular Microbiology*, vol. 13, no. 9, pp. 1410–1428, 2011.
- [21] C. Marques-da-Silva, M. M. Chaves, M. L. Thorstenberg et al., “Intralesional uridine-5'-triphosphate (UTP) treatment induced resistance to *Leishmania amazonensis* infection by boosting Th1 immune responses and reactive oxygen species production,” *Purinergic Signal*, vol. 14, no. 2, pp. 201–211, 2018.
- [22] A. C. A. Moreira-Souza, C. L. C. Almeida-da-Silva, T. P. Rangel et al., “The P2X₇ receptor mediates *Toxoplasma gondii* control

- in macrophages through canonical NLRP3 inflammasome activation and reactive oxygen species production," *Frontiers in Immunology*, vol. 8, article 1257, 2017.
- [23] R. G. Titus, M. Marchand, T. Boon, and J. A. Louis, "A limiting dilution assay for quantifying *Leishmania major* in tissues of infected mice," *Parasite Immunology*, vol. 7, no. 5, pp. 545–555, 1985.
- [24] M. M. Chaves, C. Canetti, and R. Coutinho-Silva, "Crosstalk between purinergic receptors and lipid mediators in leishmaniasis," *Parasites & Vectors*, vol. 9, no. 1, p. 489, 2016.
- [25] P. Scott and F. O. Novais, "Cutaneous leishmaniasis: immune responses in protection and pathogenesis," *Nature Reviews. Immunology*, vol. 16, no. 9, pp. 581–592, 2016.
- [26] S. P. Chaves, E. C. Torres-Santos, C. Marques et al., "Modulation of P2X7 purinergic receptor in macrophages by *Leishmania amazonensis* and its role in parasite elimination," *Microbes and Infection*, vol. 11, no. 10–11, pp. 842–849, 2009.
- [27] V. R. Figliuolo, S. P. Chaves, L. E. B. Savio et al., "The role of the P2X7 receptor in murine cutaneous leishmaniasis: aspects of inflammation and parasite control," *Purinergic Signal*, vol. 13, no. 2, pp. 143–152, 2017.
- [28] Y. Marinho, C. Marques-da-Silva, P. T. Santana et al., "MSU crystals induce sterile IL-1 β secretion via P2X7 receptor activation and HMGB1 release," *Biochimica et Biophysica Acta (BBA) - General Subjects*, vol. 1864, article 129461, 2020.
- [29] L. E. B. Savio, M. P. de Andrade, C. G. da Silva, and R. Coutinho-Silva, "The P2X7 receptor in inflammatory diseases: angel or demon?," *Frontiers in Pharmacology*, vol. 9, p. 52, 2018.
- [30] R. V. H. de Carvalho, W. A. Andrade, D. S. Lima-Junior et al., "Leishmania lipophosphoglycan triggers caspase-11 and the non-canonical activation of the NLRP3 inflammasome," *Cell Reports*, vol. 26, no. 2, pp. 429–437.e5, 2019.
- [31] D. S. Zamboni and D. S. Lima-Junior, "Inflammasomes in host response to protozoan parasites," *Immunological Reviews*, vol. 265, no. 1, pp. 156–171, 2015.
- [32] D. S. Zamboni and D. L. Sacks, "Inflammasomes and Leishmania: in good times or bad, in sickness or in health," *Current Opinion in Microbiology*, vol. 52, pp. 70–76, 2019.
- [33] R. V. H. de Carvalho, A. L. N. Silva, L. L. Santos, W. A. Andrade, K. S. G. de Sa, and D. S. Zamboni, "Macrophage priming is dispensable for NLRP3 inflammasome activation and restriction of *Leishmania amazonensis* replication," *Journal of Leukocyte Biology*, vol. 106, no. 3, pp. 631–640, 2019.
- [34] D. S. Lima-Junior, T. W. P. Mineo, V. L. G. Calich, and D. S. Zamboni, "Dectin-1 activation during *Leishmania amazonensis* phagocytosis prompts Syk-dependent reactive oxygen species production to trigger inflammasome assembly and restriction of parasite replication," *Journal of Immunology*, vol. 199, no. 6, pp. 2055–2068, 2017.
- [35] C. Pellegrini, L. Antonioli, G. Lopez-Castejon, C. Blandizzi, and M. Fornai, "Canonical and non-canonical activation of NLRP3 inflammasome at the crossroad between immune tolerance and intestinal inflammation," *Front Immunology*, vol. 8, article 36, 2017.
- [36] V. R. Figliuolo, S. P. Chaves, L. E. B. Savio et al., "Toll or interleukin-1 receptor (TIR) domain-containing adaptor inducing interferon- β (TRIF)-mediated caspase-11 protease production integrates toll-like receptor 4 (TLR4) protein- and Nlrp3 inflammasome-mediated host defense against enteropathogens," *The Journal of Biological Chemistry*, vol. 287, no. 41, pp. 34474–34483, 2012.
- [37] N. Kayagaki, M. T. Wong, I. B. Stowe et al., "Noncanonical inflammasome activation by intracellular LPS independent of TLR4," *Science*, vol. 341, no. 6151, pp. 1246–1249, 2013.
- [38] F. A. Amaral, V. V. Costa, L. D. Tavares et al., "NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B (4) in a murine model of gout," *Arthritis and Rheumatism*, vol. 64, no. 2, pp. 474–484, 2012.
- [39] G. Corrêa, C. M. da Silva, A. C. de Abreu Moreira-Souza, R. C. Vommaro, and R. Coutinho-Silva, "Activation of the P2X7 receptor triggers the elimination of *Toxoplasma gondii* tachyzoites from infected macrophages," *Microbes and Infection*, vol. 12, no. 6, pp. 497–504, 2010.
- [40] R. Coutinho-Silva, L. Stahl, M. N. Raymond et al., "Inhibition of chlamydial infectious activity due to P2X7R-dependent phospholipase D activation," *Immunity*, vol. 19, no. 3, pp. 403–412, 2003.
- [41] A. C. A. Moreira-Souza, Y. Marinho, G. Correa et al., "Pyrimidineric receptor activation controls *Toxoplasma gondii* infection in macrophages," *PLoS One*, vol. 10, no. 7, article e0133502, 2015.
- [42] H. Jin and H. J. Kim, "NLRC4, ASC and caspase-1 are inflammasome components that are mediated by P2Y2R activation in breast cancer cells," *International Journal of Molecular Sciences*, vol. 21, no. 9, p. 3337, 2020.
- [43] R. Coutinho-Silva, L. A. Alves, W. Savino, and P. M. Persechini, "A cation non-selective channel induced by extracellular ATP in macrophages and phagocytic cells of the thymic reticulum," *Biochimica et Biophysica Acta*, vol. 1278, no. 1, pp. 125–130, 1996.
- [44] R. Coutinho-Silva and P. M. Persechini, "P2Z purinoceptor-associated pores induced by extracellular ATP in macrophages and J774 cells," *American Journal of Physiology*, vol. 273, pp. C1793–C1800, 1997.
- [45] S. C. Hung, C. H. Choi, N. Said-Sadier et al., "P2X4 assembles with P2X7 and pannexin-1 in gingival epithelial cells and modulates ATP-induced reactive oxygen species production and inflammasome activation," *PLoS One*, vol. 8, no. 7, article e70210, 2013.